Skip to content
Search

Latest Stories

BREAKING: 61 per cent candidates pass first four-country common registration test for pharmacists

Just over 60 per cent candidates have passed the first four-country common registration test or assessment for pharmacists, held jointly by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI).

Out of a total of 959 candidates who sat the assessment in four countries on 16 November, 584 candidates have passed -- recording an overall pass rate of 60.9 per cent.


The registration assessment is one of the ways trainee pharmacists can demonstrate that they understand how to apply knowledge appropriately and in a timely way, to make professional judgements in pharmacy practice.

Passing the registration assessment is a vital element of being eligible to apply to become a registered pharmacist.

In the November assessment, 43 per cent candidates sat for the first time, 45 per cent for the second time and 12 per cent for the third time.

In comparison, for the July sittings 90 per cent of candidates were sitting for the first time, eight per cent were sitting for the second time and two per cent were sitting for the third time.

Trainee pharmacists are permitted three attempts at the registration assessment.

This autumn’s pass rate of 61 per cent compares with the 69 per cent pass rate for the autumn 2019 registration assessment, and the 65 per cent pass rate for the Autumn 2018 registration assessment.

For this sitting, 30 per cent of the candidates in Great Britain were provisionally-registered pharmacists.

This compares with nine per cent of candidates who sat in July and 77 per cent of candidates who sat in March.

Congratulating the the successful candidates and thanking them for their hard work and dedication in a challenging time, GPhC chief executive Duncan Rudkin said: “There will be candidates who unfortunately did not pass, and we understand they will be disappointed by this news. We hope that they will use the guidance we have produced to help them with their next steps and understand their options.”

He added that each assessment this autumn had to be carried out simultaneously across the four countries "to ensure a fair and robust process".

PSNI chief executive Trevor Patterson said: “We are delighted that the four-country Common Registration Assessment, held jointly with the GPhC , has been successfully and safely delivered during the ongoing pandemic and we are grateful to colleagues in the GPhC for their support and assistance in Northern Ireland.

“We congratulate all those candidates who have been successful and wish them every success in their future careers as much needed additions to the healthcare workforce.

“Those candidates in Northern Ireland who have been unsuccessful should refer to guidance on the Pharmaceutical Society NI website for further help and support on next steps.”

Table 1: November 2021 summary statistics

CandidatesNumber% of total
Total number of candidates959100%
Number of first time sitters41443.2%
(of which were provisionally-registered)(283)(29.5%)
Number of second time sitters43345.2%
Number of third time sitters11211.7%
 
Candidate performance - pass rates 
First sitting candidates - pass24458.9%
(of which were provisionally-registered - pass)17662.2%)
Second time sitters - pass27262.8%
Third time sitters - pass6860.7%
 
Overall pass 58460.9%
Overall fail37539.1%

Source: GPhC

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less